EichorEICHOR
Condition: Poorly Differentiated Thyroid Gland Carcinoma Synced from ClinicalTrials.gov · August 02, 2026

Recruiting studies: Poorly Differentiated Thyroid Gland Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Phase 2 · 2 location(s) · Jochen Lorch · NCT06959641Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NA · 1 location(s) · Zhejiang Provincial People's Hospital · NCT07068542Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230[177Lu]Lu-AKIR001 First-in-human Study
EARLY_Phase 1 · 1 location(s) · Karolinska University Hospital · NCT06639191
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.